Live feed
·
PRReleasevia Quantisnow
Bluejay Diagnostics Inc. logo

Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026

ByQuantisnow·Wall Street's wire, on your screen.
BJDX· Bluejay Diagnostics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BJDX (Bluejay Diagnostics Inc.) and more on Quantisnow.